Drugs like DPP-IV inhibitors, GLP-1 agonists, FXR agonists, and SGLT2 inhibitors might be useful in the treatment of NAFLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.